Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1Gynecologic 1

Conditions

Sarcoma 19Ovarian Neoplasms 11Neoplasms 7Liposarcoma 7Leiomyosarcoma 7Neoplasm Metastasis 4Sarcoma, Ewing 3Breast Neoplasms 3Solitary Fibrous Tumors 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Neoplasms by Site 2Liposarcoma, Myxoid 2Histiocytoma, Malignant Fibrous 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor, Protocol Specific 1Soft Tissue Neoplasms 1Skin Diseases 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Recurrent High Grade Meningioma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Epithelial Cancer Recurrent 1Ovarian Diseases 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × Trabectedin × Clear all
NCT00786838 2014-04-11

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
76 enrolled 17 charts
BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00580112 2014-02-25

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
127 enrolled
Breast

Breast Neoplasms

NCT00050427 2011-04-28

A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
53 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡